Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.
Guilherme De Caro MartinsAdriane Pimenta da Costa-ValFernanda Morcatti CouraGabriela Matoso Lima DiamantinoMarina Moller NogueiraOtoni Alves de Oliveira Melo-JuniorRodolfo Cordeiro GiunchettiDenise da Silveira-LemosMarilia Martins MeloPublished in: Veterinary dermatology (2021)
Oclacitinib, when administered at the currently labelled dose for one year, is associated with a significant increase in circulating CD4+ T cells, but does not alter cytokine production from antigen-stimulated T cells. The results reported do not support evidence for immunosuppression mediated by the mechanisms evaluated in this study.
Keyphrases